Angelita & Joaquim Gama Institute, São Paulo, Brazil.
Dis Colon Rectum. 2013 Jan;56(1):6-13. doi: 10.1097/DCR.0b013e318273f56f.
Significant tumor downstaging among patients with rectal cancer following neoadjuvant chemoradiation has raised the issue of offering patients with small residual cancers restricted to the bowel wall an alternative treatment strategy to total mesorectal excision. Transanal endoscopic microsurgery may allow proper primary tumor resection with promising oncological outcomes, less postoperative morbidity, and minimal long-term sexual, urinary, and fecal continence disorders in comparison with radical resection.
The aim of this study was to determine the oncological outcomes of patients with residual rectal cancers restricted to the rectal wall (ypT0-2) following neoadjuvant chemoradiation and transanal endoscopic microsurgery.
This study considered a prospective cohort of patients with residual rectal cancers following neoadjuvant chemoradiation treated by transanal endoscopic microsurgery and no additional systemic therapy.
This study was a single-institution experience.
Patients with adenocarcinoma of the rectum located no more than 7 cm from the anal verge and endorectal ultrasound- or magnetic resonance-staged cT2-4N0-2M0 treated by neoadjuvant chemoradiation (50.4-54 Gy and 5-fluorouracil-based chemotherapy) were eligible for the study. Patients with small residual tumors (≤3 cm) radiologically staged ycT0-2N0 were treated by transanal endoscopic microsurgery.
Transanal endoscopic microsurgery was performed.
The primary outcome measured was local recurrence.
Of the 27 patients treated by transanal endoscopic microsurgery, 3 had ypT0, 6 had ypT1, and 18 had ypT2 cancers. All patients underwent R0 transanal endoscopic microsurgery excision. Local recurrence was observed in 4 (15%) patients after a median follow-up of 15 months. Only lymphovascular invasion was an independent predictive factor for local failure (p = 0.04). Tumor size, ypT status, T-status downstaging, lateral/radial margins, and tumor regression grade were not predictors of local failure.
This study was limited by the small sample size and limited follow-up.
A local failure rate of 15% after transanal endoscopic microsurgery for patients with residual rectal cancers restricted to the bowel wall (ypT0-2) may limit the indication of this procedure to highly selected patients as an alternative to standard radical total mesorectal excision.
新辅助放化疗后直肠癌患者肿瘤明显降期,这引发了一个问题,即对于残留小肿瘤局限于肠壁的患者,是否可以采用一种替代标准全直肠系膜切除术(total mesorectal excision)的治疗策略。与根治性切除术相比,经肛门内镜微创手术(transanal endoscopic microsurgery)可能允许对原发肿瘤进行适当的切除,并获得良好的肿瘤学结果,同时术后发病率更低,且长期性功能、尿便失禁障碍更小。
本研究旨在确定新辅助放化疗后接受经肛门内镜微创手术治疗且无其他全身治疗的残留直肠壁内直肠癌(ypT0-2)患者的肿瘤学结局。
本研究纳入了一组新辅助放化疗后接受经肛门内镜微创手术治疗且无额外全身治疗的残留直肠腺癌患者的前瞻性队列研究。
本研究为单中心经验。
本研究纳入的患者为距肛缘不超过 7 cm、直肠内超声或磁共振分期为 cT2-4N0-2M0 的直肠腺癌患者,接受新辅助放化疗(50.4-54 Gy 和 5-氟尿嘧啶为基础的化疗)。对于影像学分期为 ycT0-2N0 的小残留肿瘤(≤3 cm)患者,行经肛门内镜微创手术治疗。
行经肛门内镜微创手术。
主要观察终点为局部复发。
在接受经肛门内镜微创手术治疗的 27 例患者中,3 例患者为 ypT0 期,6 例患者为 ypT1 期,18 例患者为 ypT2 期。所有患者均行 R0 经肛门内镜微创手术切除。中位随访 15 个月后,4 例(15%)患者出现局部复发。仅脉管侵犯是局部失败的独立预测因素(p = 0.04)。肿瘤大小、ypT 分期、T 分期降期、侧向/放射状切缘和肿瘤退缩分级均不是局部失败的预测因素。
本研究受到样本量小和随访时间有限的限制。
对于残留直肠壁内(ypT0-2)直肠癌患者,经肛门内镜微创手术后局部复发率为 15%,这可能限制了该手术作为标准根治性全直肠系膜切除术替代治疗的适应证,仅适用于高度选择的患者。